Results 191 to 200 of about 93,221 (259)

European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids

Journal of Neuroendocrinology, Volume 38, Issue 4, April 2026.
Abstract This ENETS guidance paper, developed by a multidisciplinary working group, provides up‐to‐date and practical advice on the diagnosis and management of lung and thymic carcinoids, based on recent developments and study results. These recommendations aim to provide practical recommendations for the diagnosis, treatment and follow‐up of these ...
Eric Baudin, Alice Durand, Wieneke Buikhuisen, Jaume Capdevila, Martyn Caplin, Christophe M. Deroose, Clarisse Dromain, Antongiulio Faggiano, Pier Luigi Filosso, Gregory Kaltsas, Marco Volante, Thomas Walter, Rocio Garcia‐Carbonero   +12 more
wiley   +1 more source

Impact of neuroendocrine neoplasm-specific systemic treatments on expression and function of CXCR4 in neuroendocrine tumor cells. [PDF]

Sci Rep
Däubler C, Böttcher C, Landwehr LS, Meining A, Michalski K, Reiter F, Werner RA, Hartrampf P, Rogoll D, Weich A.   +9 more
europepmc   +1 more source

MR‐Guided Laser Interstitial Thermal Therapy for Recurrent Glioblastoma: A Case Report With Novel Insights Into Histopathological Changes and Immunological Responses

Neuropathology and Applied Neurobiology, Volume 52, Issue 2, April 2026.
MR‐guided laser interstitial thermal therapy (LITT) offers a minimally invasive option for recurrent glioblastoma, but human post‐treatment tissue data are scarce. In this case report, post‐LITT tissue exhibited distinct zonal changes, including central necrosis within the ablation zone and reduced tumour proliferation with increased CD8+ T‐cell ...
Silas Haahr Nielsen, Sara Blaabjerg Artzi, Jane Skjøth‐Rasmussen, Carl Christian Larsen, Nadine Margaretha Hammouda, Karen Bonde Larsen, Rune Rasmussen, Adam Espe Hansen, Bjarne Winther Kristensen   +8 more
wiley   +1 more source

Systemic therapy in the treatment of recurrent or refractory intracranial meningiomas: A systematic review and individual patient data meta-analysis. [PDF]

Neurosurg Rev
Mensah EO, Ghosh A, Rane A, Kim J, Bhatt PB, Alalade AF.   +5 more
europepmc   +1 more source

Mapping the global research landscape and innovations on elderly glioma: a bibliometric analysis. [PDF]

Front Oncol
Guo S, Zhao W, Liu J, Wang N, Ji P, Wang L, Wang Y.   +6 more
europepmc   +1 more source

Genomic Alteration Patterns Across Histological Grades in BRAF p.V600E‐Mutant Gliomas and Glioneuronal Tumors: An Analysis of 15 Cases

Pathology International, Volume 76, Issue 4, April 2026.
BRAF p.V600E‐mutant gliomas show substantial genomic heterogeneity across histological grades. Low‐grade tumors are generally genomically quiet, whereas high‐grade tumors tend to exhibit increased copy‐number gains. These findings highlight the limitations of genomic alteration burden as a surrogate indicator of malignant potential.
Seiji Yamada, Tetsuya Takimoto, Mina Ikeda, Eiji Sugihara, Junya Yamaguchi, Shoichi Deguchi, Kosuke Aoki, Fumiharu Ohka, Kazuya Motomura, Mayu Takeda, Shigeo Ohba, Sachiko Minamiguchi, Kennosuke Karube, Ryuta Saito, Yuichi Hirose, Hideyuki Saya   +15 more
wiley   +1 more source

Effects of temozolomide dosing on outcome in glioblastoma. [PDF]

J Neurooncol
Raghu A, Killar S, Cohen AL.
europepmc   +1 more source

Lactate Metabolism‐Immune Regulation‐Related Gene Signature in Lower‐Grade Gliomas: Prognostic Model Development and Immune Characterization

The FASEB Journal, Volume 40, Issue 6, 31 March 2026.
Lactate metabolism‐immune regulation‐related gene signature (PLA2G2A, TNFRSF12A, VAV3) predicts glioma prognosis. PLA2G2A promotes ECM remodeling, tumor‐associated inflammation, and EMT, leading to enhanced proliferation, invasion, and unfavorable outcomes.
Enhao Zhang, Liangzhe Wei, He Ren, Jianfei Zhang, Hongqiao Yang, Meng Sun, Xiang Gao, Yi Huang   +7 more
wiley   +1 more source

Retraction Note: Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. [PDF]

Sci Rep
Bai Y, Chen Y, Hong X, Liu X, Su X, Li S, Dong X, Zhao G, Li Y.   +8 more
europepmc   +1 more source

Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor. [PDF]

Curr Oncol
Guo J, Lewis KA, Prakash L, Bhosale P, Morani A, Katz MHG, Tzeng CD, Ikoma N, Snyder R, Kim MP, Chandrasekharan C, Dasari A, Yao JC, Lee JE, Maxwell JE, Halperin DM.   +15 more
europepmc   +1 more source